Granules India has received Establishment Inspection Report (EIR), from the US health regulator for facility in Telangana.

The US Food and Drug Administration inspected Jeedimetla facility (Hyderabad) in March 2018 and issued one 483 observation during the inspection and the company has also stated that, it has responded to the observation within the stipulated time frame.

Further, Jeedimetla facility manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFIs).

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week